Rakovina Therapeutics Announces Three-Month Q3 ended September 30, 2025 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended September 30, 2025 (“Q3 2025”), and provided an update on recent corporate developments. Q3 2025 Financial Highlights Reported a net loss ...